Ginkgo Bioworks Reports Third Quarter 2026 Results; Signs First Autonomous Lab Sale to a Top-Tier Pharma Company Novo
Business Wire•05/11/2026•16:05 ET
0
Key Highlights
- ➤Q3 revenue $28 million, down 6% year over year
- ➤Adjusted EBITDA loss $22 million, improved from $53 million
- ➤Ginkgo sold its first autonomous lab to pharma company Novo
- ➤ARPA-H subcontract worth up to $17.5 million expands autonomous lab manufacturing
- ➤Ginkgo reaffirms 2026 cash burn guidance of ($150)-($125) million
Expert Statements
Jason Kelly, Co-founder and CEO of Ginkgo Bioworks
“Ginkgo now has two core offerings built on one autonomous lab platform”
Jason Kelly, Co-founder and CEO of Ginkgo Bioworks
“This quarter we announced the sale of an autonomous lab to a top-tier pharma company, Novo, alongside new government wins with ARPA-H and the NSF.”
Jason Kelly, Co-founder and CEO of Ginkgo Bioworks
“Our Cloud Lab runs experiments on Nebula, the world's largest autonomous lab, giving pharma an onshore alternative to overseas CROs and giving frontier AI labs a new engine for training data.”
Jason Kelly, Co-founder and CEO of Ginkgo Bioworks
“With the U.S. government now treating autonomous labs as national infrastructure, we believe Ginkgo is well positioned to lead the transition from the bench to autonomous research.”
Ginkgo Bioworks Reports Third Quarter 2026 Results; Signs First Autonomous Lab Sale to a Top-Tier Pharma Company Novo
Ginkgo provides an update on its third quarter financial results and the growth of its two prevailing offerings built on one autonomous lab platform: Autonomous Labs and Cloud Lab
Get started
Create a free account to read the full story.